Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 2/20 | 0.58 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8526862 | 0.93 | P2RX4 (0.55) | P2RX4CTRB1P2RX1P2RX3NPC1 | |
| SCHEMBL8777369 | 0.91 | P2RX4 (0.50) | P2RX4CTRB1P2RX1P2RX3NPC1 | |
| SCHEMBL12474901 | 0.87 | NPC1 (0.63) | P2RX4CTRB1P2RX1P2RX3NPC1 | |
| SCHEMBL11404740 | 0.84 | HTR1A (0.47) | P2RX4CTRB1P2RX1P2RX3NPC1 | |
| SCHEMBL6343082 | 0.83 | ALDH1A1 (0.43) | P2RX4CTRB1P2RX1P2RX3NPC1 | |
| SCHEMBL22184884 | 0.83 | HTR2C (0.55) | P2RX4CTRB1P2RX1P2RX3NPC1 | |
| SCHEMBL876243 | 0.81 | SMN1; SMN2 (0.49) | P2RX4CTRB1P2RX1P2RX3NPC1 | |
| SCHEMBL29235094 | 0.81 | NPC1 (0.61) | P2RX4CTRB1P2RX1P2RX3NPC1 | |
| SCHEMBL19984711 | 0.81 | P2RX4 (0.64) | P2RX4CTRB1P2RX1P2RX3NPC1 | |
| SCHEMBL2539997 | 0.80 | NPC1 (0.67) | P2RX4CTRB1P2RX1P2RX3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 489 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119564933-A | Preparation method of biological tissue material, prepared biological tissue material and application | 上海易桥医疗器械有限公司 | 2025-03-07 | — | — | CN | claimed |
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | claimed |
| WO-2024024935-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE HAVING ANTINEOPLASTIC EFFECT | 第一三共株式会社 | 2024-02-01 | — | — | WO | claimed |
| EP-4286393-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2023-12-06 | — | — | EP | claimed |
| CN-116867795-A | Novel method for producing antibody-immunostimulant conjugate | 第一三共株式会社 | 2023-10-10 | — | — | CN | claimed |
| CN-116410145-A | Preparation method of MRTX849 intermediate | 上海泓博智源医药股份有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-112898204-B | Synthesis method of N-carbobenzoxy-L-histidine | 苏州昊帆生物股份有限公司 | 2023-05-12 | — | — | CN | claimed |
| WO-2022163846-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | 第一三共株式会社 | 2022-08-04 | — | — | WO | claimed |
| CN-112898204-A | Synthesis method of N-benzyloxycarbonyl-L-histidine | 苏州昊帆生物股份有限公司 | 2021-06-04 | — | — | CN | claimed |
| CN-110698381-A | Method for synthesizing N- (benzyloxycarbonyl) succinimide by one-pot two-phase method | 常州吉恩药业有限公司 | 2020-01-17 | — | — | CN | claimed |
| EP-0406734-A2 | 2-(Aminoaryl)indoles and indolines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-01-09 | — | — | EP | claimed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3810615-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4656626-A1 | COMPOUND AND METHOD FOR USING SAME, PLASTICIZER COMPOSITION, RESIN COMPOSITION, RESIN MOLDED BODY, AND LAMINATED BODY | Zeon Corporation (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-4615581-A2 | FUSED MULTICYCLIC COMPOUNDS AND THEIR USE AS PARP1 INHIBITORS | Laekna Pharmaceutical Ningbo Co., Ltd. (CN) | 2025-09-17 | — | — | EP | disclosed |
| US-4331804-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1982-05-25 | — | — | US | disclosed |
| US-4196197-A | 2'N-Acyl and alkyl-6'-N-alkyl- and 6',6'-di-N-alkyl derivatives of fortimicins A and B | ABBOTT LABORATORIES (US) | 1980-04-01 | — | — | US | disclosed |
| US-4187297-A | 3-De-O-methyl-2-N-acyl and alkyl fortimicins A and B | ABBOTT LABORATORIES (US) | 1980-02-05 | — | — | US | disclosed |
| US-4183920-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1980-01-15 | — | — | US | disclosed |
| US-4166114-A | AMINOGLYCOSIDE ANTIBIOTIC DERIVATIVES AND METHOD OF USE | SHIONOGI & CO., LTD. (JP) | 1979-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | PAICS, COASY, CDS2 | P2RX4 1259/4885CTRB1 2556/4885P2RX1 1548/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | P2RX4 4483/4885CTRB1 28/4885P2RX1 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.